Form 4: Neurocrine Biosciences Executive Receives Stock Grant
Insider Transaction (Form 4)
Sanjay Chandru Keswani, Chief Medical Officer of Neurocrine Biosciences Inc, reported multiple transactions in common stock on September 11, 2026.
Summary
- Grant/award: acquired 3,914 Common Stock on September 11, 2026; holds 5,393 after (Direct).
- Tax/exercise-price withholding: disposed of 2,112 Common Stock at $156.22 ($329,937) on September 11, 2026; holds 3,281 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Sanjay Chandru Keswani — Officer (Chief Medical Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-11 | Grant/award | Common Stock | 3,914 | — | — | 5,393 |
| 2026-09-11 | Tax/exercise-price withholding | Common Stock | 2,112 | $156 | $329.9K | 3,281 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-11 | Grant/award (3,914 shares) |
| 2026-09-11 | Tax/exercise-price withholding (2,112 shares) |
Keywords
insider transaction, Form 4, NBIX, NEUROCRINE BIOSCIENCES INC, neutral, Sanjay Chandru Keswani
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.